The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial

Alon Eisen, Christopher P. Cannon, Michael A. Blazing, Erin A. Bohula, Jeong Gun Park, Sabina A. Murphy, Jennifer A. White, Robert P. Giugliano, Eugene Braunwald

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To examine the efficacy and safety of ezetimibe added to statin in patients with prior coronary artery bypass graft surgery (CABG) following hospitalization for an acute coronary syndrome (ACS). Methods and results: In the IMPROVE-IT trial, post-ACS patients with mean low density lipoprotein cholesterol (LDL-C) of 93.8mg/dL at presentation were randomized to simvastatin/ezetimibe or simvastatin/placebo. The primary endpoint was cardiovascular death, major coronary event or stroke, and the median follow-up was 6 years. Efficacy and safety endpoints were examined by prior CABG status. Among 18134 patients, 1684 (9.3%) had a prior CABG (median age 69 years, 82% male). During the trial, the median time-weighted LDL-C level was 55.0mg/dL with simvastatin/ezetimibe vs. 69.9mg/dL with simvastatin/placebo in patients with prior CABG (P < 0.001), and it was 53.6mg/dL vs. 69.5 mg/dL, respectively, in patients without prior CABG (P < 0.001). The rate of the primary endpoint was higher in patients with vs. without prior CABG [56% vs. 32%, adj. hazard ratio 1.45, 95% confidence interval (CI) 1.33-1.58]. Patients with prior CABG receiving simvastatin/ezetimibe had an 8.8% (95% CI 3.1-14.6%) lower absolute risk over simvastatin/placebo in the primary endpoint, whereas patients without prior CABG had a 1.3% (95% CI 0-2.6%) lower absolute risk (P-interaction - 0.02). There were no between-group significant differences in safety endpoints. Conclusion: The clinical benefit of adding ezetimibe to statin appears to be enhanced in patients with prior CABG, supporting the use of intensive lipid lowering therapy in these high-risk patients following ACS.

Original languageEnglish
Pages (from-to)3576-3584
Number of pages9
JournalEuropean Heart Journal
Volume37
Issue number48
DOIs
StatePublished - 21 Dec 2016
Externally publishedYes

Keywords

  • Acute coronary syndrome •cardiovascular events
  • Coronary artery bypass graft
  • Ezetimibe
  • Statin

Fingerprint

Dive into the research topics of 'The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial'. Together they form a unique fingerprint.

Cite this